Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference
Portfolio Pulse from Benzinga Newsdesk
Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced that Phase 2 results of Haduvio for chronic cough will be presented at the ATS 2024 Conference in San Diego, CA, on May 19th. Haduvio is being developed for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
April 09, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Trevi Therapeutics, Inc. is set to present Phase 2 results of Haduvio for chronic cough at the ATS 2024 Conference, potentially impacting its stock positively.
The presentation of positive Phase 2 trial results at a significant conference like ATS 2024 can lead to increased investor confidence in Trevi Therapeutics and its investigational therapy, Haduvio. This could potentially lead to a positive short-term impact on TRVI's stock price, as successful trial results are a critical factor in the biopharmaceutical industry's development and commercialization process.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100